Drugs / Samarium 153
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00328614 | Mar 2003 → Feb 2009 | prostate cancer | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00551525 | Apr 2008 → Jul 2014 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00365105 | Jul 2006 → Jan 2012 | breast cancer, lung cancer, metastatic malignant neoplasm, prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Samarium-153 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00328614 ↗ |
| Known as | Sm-153 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00365105 ↗ |
| Route | Intravenous | “Single dose intravenously 1 mCi/kg body weight” NCT00365105 ↗ |